secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2022-04-25T23:59:59+00:00
Accession:  0001728117-22-000035
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Phase 2 SHIFT-UC trial of GB004 misses primary endpoint; study terminated
--------------------------------------------------------------------------------

- Phase 2 trial of GB004 in mild-to-moderate active UC failed primary endpoint at week 12 (15.4% QD, 22.5% BID vs. placebo 17.9%).
- No meaningful differences on secondary endpoints; Gossamer terminates treat-through and open-label extension portions.
- Preliminary cash, cash equivalents, and marketable securities ~$272M as of March 31, 2022 (unaudited).
- Target enrollment of 80 patients reached in Phase 2 TORREY trial of seralutinib in PAH; topline results expected Q4 2022.
- Anticipates initiation of Phase 1b/2 STAR CNS trial of GB5121 in primary CNS lymphoma in late Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000035/0001728117-22-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000035/goss-20210425x8k.htm
  HTML page:      https://secwatch.observer/filing/0001728117-22-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer